Inventor · disambiguated record
Nicholas Erho
Also filed as: ERHO NICHOLAS · ERHO NICHOLAS GEORGE
8 granted patents·12 pending applications·24 citations·filing 2012–2025
82Inventor score
Files withDECIPHER BIOSCIENCES INC9VERACYTE SD INC6GENOMEDX BIOSCIENCES INC2VERACYTE INC2DAVICIONI ELAI1
Top patents by PatentIndex Score
20 records- 0187US10513737B2Cancer diagnostics using non-coding transcriptsDECIPHER BIOSCIENCES INC·Filed 2012·Granted Dec 24, 2019·9 cites·7 claims
- 0284US11208697B2Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 28, 2021·5 cites·11 claims
- 0384US11078542B2Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2018·Granted Aug 3, 2021·3 cites·3 claims
- 0482US11414708B2Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyDECIPHER BIOSCIENCES INC·Filed 2017·Granted Aug 16, 2022·3 cites·9 claims
- 0579US2025171854A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessVERACYTE INC·Filed 2024·Application pending·0 cites
- 0677US2025327136A1Systems and methods for preprocessing target data and generating predictions using a machine learning modelVERACYTE SD INC·Filed 2025·Application pending·0 cites
- 0774US2024417800A1Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancerVERACYTE INC·Filed 2024·Application pending·0 cites
- 0871US12378610B2Systems and methods for preprocessing target data and generating predictions using a machine learning modelVERACYTE SD INC·Filed 2023·Granted Aug 5, 2025·0 cites·19 claims
- 0968US2024360517A1Subtyping prostate cancer to predict response to hormone therapyVERACYTE SD INC·Filed 2024·Application pending·0 cites
- 1067US2022349011A1Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1166US11035005B2Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2013·Granted Jun 15, 2021·4 cites·14 claims
- 1266US2022177974A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1365US2022325352A1Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1464US2023220485A1Cancer biomarkers and classifiers and uses thereofVERACYTE SD INC·Filed 2022·Application pending·0 cites
- 1562US2023151429A1Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyVERACYTE SD INC·Filed 2022·Application pending·0 cites
- 1660US2016032395A1Cancer biomarkers and classifiers and uses thereofDAVICIONI ELAI·Filed 2014·Application pending·0 cites
- 1753US11873532B2Subtyping prostate cancer to predict response to hormone therapyVERACYTE SD INC·Filed 2018·Granted Jan 16, 2024·0 cites·10 claims
- 1850US2018291459A1Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancerGENOMEDX BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 1945US12497660B2Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapyDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 16, 2025·0 cites·19 claims
- 2034US2019204322A1Molecular subtyping, prognosis and treatment of prostate cancerGENOMEDX BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nicholas Erho files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →